Tommy� Fornander

10.9k total citations · 1 hit paper
133 papers, 6.5k citations indexed

About

Tommy� Fornander is a scholar working on Cancer Research, Oncology and Genetics. According to data from OpenAlex, Tommy� Fornander has authored 133 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Cancer Research, 75 papers in Oncology and 64 papers in Genetics. Recurrent topics in Tommy� Fornander's work include Breast Cancer Treatment Studies (60 papers), Estrogen and related hormone effects (56 papers) and HER2/EGFR in Cancer Research (18 papers). Tommy� Fornander is often cited by papers focused on Breast Cancer Treatment Studies (60 papers), Estrogen and related hormone effects (56 papers) and HER2/EGFR in Cancer Research (18 papers). Tommy� Fornander collaborates with scholars based in Sweden, United States and United Kingdom. Tommy� Fornander's co-authors include Lars Erik Rutqvist, Hemming Johansson, Lambert Skoog, Olle Stål, Bo Nordenskjöld, Ulla Glas, Gábor Gyenes, Ingmar Lax, Nils Wilking and Jan Adolfsson and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Tommy� Fornander

132 papers receiving 6.3k citations

Hit Papers

ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF ... 1989 2026 2001 2013 1989 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERS
    1989 685 citations Tommy� Fornander, Lambert Skoog et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tommy� Fornander Sweden 45 2.9k 2.6k 2.1k 1.2k 1.2k 133 6.5k
Nicole Rotmensz Italy 66 5.6k 1.9× 7.0k 2.7× 2.0k 1.0× 1.2k 1.0× 1.5k 1.3× 223 12.0k
S. Ashley United Kingdom 47 3.1k 1.1× 2.0k 0.8× 1.2k 0.6× 679 0.6× 2.1k 1.8× 127 7.1k
David Dodwell United Kingdom 39 2.9k 1.0× 1.9k 0.7× 710 0.3× 624 0.5× 1.1k 1.0× 188 5.5k
J. Houghton United Kingdom 19 2.2k 0.8× 2.2k 0.9× 1.8k 0.9× 395 0.3× 644 0.5× 51 4.1k
Carsten Rose Denmark 38 3.1k 1.1× 4.6k 1.8× 1.0k 0.5× 1.0k 0.8× 1.0k 0.9× 115 7.2k
Elizabeth Tan-Chiu United States 22 5.2k 1.8× 3.2k 1.2× 3.2k 1.5× 1.5k 1.2× 1.1k 0.9× 48 8.7k
Jonine L. Bernstein United States 33 1.1k 0.4× 1.4k 0.5× 1.4k 0.7× 875 0.7× 574 0.5× 138 3.7k
Maureen Kavanah United States 17 3.2k 1.1× 3.5k 1.4× 3.7k 1.8× 1.2k 1.0× 661 0.6× 24 7.6k
S. Ashley United Kingdom 39 2.6k 0.9× 1.3k 0.5× 1.3k 0.6× 600 0.5× 1.5k 1.3× 80 6.1k
Nicholas J. Robert United States 44 6.7k 2.3× 4.1k 1.6× 2.2k 1.1× 2.0k 1.7× 2.0k 1.7× 181 10.0k

Countries citing papers authored by Tommy� Fornander

Since Specialization
Citations

This map shows the geographic impact of Tommy� Fornander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tommy� Fornander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tommy� Fornander more than expected).

Fields of papers citing papers by Tommy� Fornander

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tommy� Fornander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tommy� Fornander. The network helps show where Tommy� Fornander may publish in the future.

Co-authorship network of co-authors of Tommy� Fornander

This figure shows the co-authorship network connecting the top 25 collaborators of Tommy� Fornander. A scholar is included among the top collaborators of Tommy� Fornander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tommy� Fornander. Tommy� Fornander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Salunga, Ranelle, Wilma E. Mesker, Linda de Munck, et al.. (2025). Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index. Clinical Cancer Research. 31(11). 2222–2229. 1 indexed citations
2.
Nordenskjöld, Anna, Helena Fohlin, Johan Rosell, et al.. (2023). Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy. The Breast. 71. 63–68. 2 indexed citations
3.
Danielsson, Oscar, Gizeh Pérez‐Tenorio, Anna Nordenskjöld, et al.. (2023). Abstract P3-05-03: Long-term survival and intra-tumor heterogeneity of progesterone receptor expression in estrogen receptor-positive/progesterone receptor-positive premenopausal women with breast cancer. Cancer Research. 83(5_Supplement). P3–5. 1 indexed citations
4.
Eliáš, Daniel, Carla L. Alves, Martin V. Bennetzen, et al.. (2021). MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. npj Breast Cancer. 7(1). 2–2. 11 indexed citations
5.
Johansson, Annelie, Anna Nordenskjöld, Adina Iftimi, et al.. (2021). Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy. JAMA Network Open. 4(6). e2114904–e2114904. 18 indexed citations
6.
Fornander, Tommy�, et al.. (2016). Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer. British Journal of Cancer. 114(3). 248–255. 46 indexed citations
7.
Manna, Subrata, Josefine Bostner, Yang Sun, et al.. (2015). ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer. Clinical Cancer Research. 22(6). 1421–1431. 51 indexed citations
8.
Zhang, Yi, Catherine A. Schnabel, Brock E. Schroeder, et al.. (2013). Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence. Clinical Cancer Research. 19(15). 4196–4205. 163 indexed citations
9.
10.
Weiner, Maria, et al.. (2013). Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer. Annals of Oncology. 24(8). 1994–1999. 18 indexed citations
11.
McGale, Paul, Sarah C. Darby, Per Hall, et al.. (2011). Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiotherapy and Oncology. 100(2). 167–175. 364 indexed citations
12.
Johnsson, Aina, Tommy� Fornander, Lars‐Erik Rutqvist, & Mariann Olsson. (2011). Work status and life changes in the first year after breast cancer diagnosis. Work. 38(4). 337–346. 51 indexed citations
13.
Bostner, Josefine, Lambert Skoog, Tommy� Fornander, Bo Nordenskjöld, & Olle Stål. (2010). Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer. Clinical Cancer Research. 16(5). 1624–1633. 48 indexed citations
14.
Jerevall, Piiha-Lotta, Agneta Jansson, Tommy� Fornander, et al.. (2010). Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer. Breast Cancer Research. 12(4). R53–R53. 25 indexed citations
15.
16.
Aubele, Michaela, Gert Auer, Axel Walch, et al.. (2007). PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. British Journal of Cancer. 96(5). 801–807. 72 indexed citations
17.
Margolin, Sara, Barbro Werelius, Tommy� Fornander, & Annika Lindblom. (2004). BRCA1 Mutations in a Population-based Study of Breast Cancer in Stockholm County. Genetic Testing. 8(2). 127–132. 16 indexed citations
18.
Skog, Sven, et al.. (2003). Determination of serum thymidine kinase 1 by anti-TK1 antibody A potential indicator for diagnoses of tumor and monitoring of therapy. Clinical Chemistry. 49. 100–101. 1 indexed citations
19.
Fornander, Tommy�, et al.. (1997). Detection of radiation-induced myocardial damage by technetium-99m sestamibi scintigraphy. European Journal of Nuclear Medicine and Molecular Imaging. 24(3). 286–292. 17 indexed citations
20.
Rutqvist, Lars Erik, et al.. (1995). Adjuvant Tamoxifen Therapy for Early Stage Breast Cancer and Second Primary Malignancies. JNCI Journal of the National Cancer Institute. 87(9). 645–651. 402 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicole Rotmensz Breakdown of academic impact, for papers by S. Ashley Breakdown of academic impact, for papers by David Dodwell Breakdown of academic impact, for papers by J. Houghton Breakdown of academic impact, for papers by Carsten Rose Breakdown of academic impact, for papers by Elizabeth Tan-Chiu Breakdown of academic impact, for papers by Jonine L. Bernstein Breakdown of academic impact, for papers by Maureen Kavanah Breakdown of academic impact, for papers by S. Ashley Breakdown of academic impact, for papers by Nicholas J. Robert
Rankless by CCL
2026